Announcements

Calgary’s Amanda Hall wins the $1-million Women in Cleantech Challenge

12/09/2021

After three years of navigating the ups and downs of building a new company, the founder and CEO of Summit Nanotech accepted the prize virtually at MaRS Climate Impact. Excerpt from the Press Release: Amanda Hall is now $1 million closer to helping Canada reach its net-zero goals. Today, Hall, founder and CEO of Calgary-based startup Summit…

Read More

Freenome Partners with Siemens Healthineers for Breast Cancer Research

12/09/2021

— Collaboration leverages imaging, diagnostic and multiomic expertise to identify new, significant biomarkers to improve the detection of breast cancer Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2021 /PRNewswire/ — Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify…

Read More

RefleXion Receives Breakthrough Device Designation for Lung Cancer Treatment

12/08/2021

Lungs among most common site for metastatic tumors Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, Inc., a therapeutic oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT lies…

Read More

New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing

12/08/2021

Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications Excerpt from the Press Release: CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ — For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target…

Read More

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

12/08/2021

Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable…

Read More

Pfizer testing its vaccine against new COVID-19 strain

12/03/2021

Excerpt from the Press Release: Pfizer said Friday that it can produce a COVID-19 vaccine for the new virus strain identified in South Africa in “approximately 100 days,” subject to government regulatory approval. The pharmaceutical firm said in a statement to CBS MoneyWatch that its researchers are now conducting tests to see if the company’s existing vaccine is effective…

Read More

New funding from the Ontario Institute for Cancer Research supports projects developing methods for cancer detection and tools to facilitate better treatment decisions for high-risk cancer patients

12/03/2021

December 1, 2021—Toronto— Today the Ontario Institute for Cancer Research (OICR) announced renewed funding for its Adaptive Oncology (AO) research theme, which includes funding for three new research projects with the potential to have rapid clinical impact. Excerpt from the Press Release: he Adaptive Oncology theme was developed to anticipate and counter tumour evolution and…

Read More

Strategy to overcome tumors’ resistance to immunotherapy generates promising clinical trial results

12/03/2021

Responses to immune checkpoint inhibitors improved after adding radiation therapy. Date:November 18, 2021 Source:Massachusetts General Hospital Summary:Immune checkpoint inhibitors strengthen the immune response against cancer cells, but the medications are ineffective against certain tumors. Results from a new clinical trial indicate that adding radiation may overcome this resistance to immune checkpoint inhibitors. Excerpt from the…

Read More

A CDMO balancing act: Offering greater speed to market while adhering to regulatory requirements

12/02/2021

Mark W. Womack, CEO of Stelis Biopharma, shares his views on the speed and compliance balancing act to achieve quality during a contract manufacturing operation. Excerpt from the Press Release: The onset of the Covid-19 pandemic brought with it the exigent need for extraordinarily rapid development of treatments and vaccines to defend against a novel…

Read More